Camrelizumab

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Resectable Esophageal Squamous Cell Carcinoma

Conditions

Resectable Esophageal Squamous Cell Carcinoma

Trial Timeline

Sep 1, 2021 → Dec 31, 2030

NCT ID

NCT05043688

About Camrelizumab

Camrelizumab is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Resectable Esophageal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05043688. Target conditions include Resectable Esophageal Squamous Cell Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05547737	Pre-clinical	UNKNOWN	Sep 21, 2022	Sep 21, 2025	NSCLC
NCT05093140	Phase 2	UNKNOWN	Jun 1, 2022	Dec 1, 2024	Primary Extranodal Lymphoma
NCT05043688	Phase 3	Recruiting	Sep 1, 2021	Dec 31, 2030	Resectable Esophageal Squamous Cell Carcinoma
NCT04805736	Phase 2	Completed	Mar 25, 2021	Apr 30, 2023	Breast Cancer
NCT05099848	Phase 2	UNKNOWN	Mar 17, 2021	Dec 31, 2024	Hepatocellular Carcinoma
NCT03912857	Phase 2	UNKNOWN	Dec 1, 2018	Jun 1, 2020	Metastatic Colorectal Cancer
NCT02742935	Phase 1	Completed	Apr 27, 2016	May 6, 2019	Solid Tumor

Competing Products

20 competing products in Resectable Esophageal Squamous Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
ateganosine + Cadonilimab	MAIA Biotechnology	Phase 1	25
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	23
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	33
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	23
zolbetuximab	Astellas Pharma	Pre-clinical	23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	77
zolbetuximab	Astellas Pharma	Pre-clinical	23
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	77
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	77
ASP1948	Astellas Pharma	Phase 1	33
mFOLFOX7 combined with Camrelizumab and apatinib	Sun Pharmaceutical	Phase 2	52
Lenvatinib	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 1	33
Lenvatinib	Eisai	Phase 1/2	41
Nivolumab + Everolimus	Ono Pharmaceutical	Phase 3	77
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + Cetuximab	Ono Pharmaceutical	Phase 1	33
SHR-4602	Jiangsu Hengrui Medicine	Phase 2	52
SHR-1210 + Apatinib + Sorafenib	Jiangsu Hengrui Medicine	Phase 3	77
SHR-1210	Jiangsu Hengrui Medicine	Phase 2	52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved